A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.

A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01285817

Acronym

SFCE METRO 01

Enrollment

Registered

2011-01-28

Start date

2011-01-12

Completion date

2023-03-09

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Survival Without Progression

Brief summary

To establish the anti-tumour effect of this metronomic combination regimen defined by progression-free survival (PFS) after two cycles of treatment (4 months) and 12 months of treatment, as well as response rate after any number of cycles of treatment (best response). To define the safety profile of the combination. To characterize pharmacodynamics of the drug combination with the use of angiogenic markers (CEP, CEC, microparticles).

Detailed description

Multi-center, combination phase II study, open-label, non-comparative, non-randomized. All progressive or recurrent solid tumours will be included in the Phase II study, provided there are no curative options anymore. Total expected number of patients (minimum maximum): 54 to 90 (2-stage design)

Interventions

DRUGcelecoxib, Vinblastine, Cyclophosphamide , methotrexate ,

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

4 Years to 21 Years

Healthy volunteers

Inclusion criteria

* Patients must have a histologically or cytologically confirmed malignant solid tumour. * Progression or recurrence of the tumour radiologically established or confirmed within the 4 weeks prior to inclusion. * Disease must be considered refractory to any line of conventional therapy or for which no effective conventional treatment exists. * Age: ≥4 to 21 years of age at study entry * Life expectancy: at least 8 weeks * ECOG Performance status ≤ 1 or Lansky-Play Scale ≥ 70% * Written informed consent of parent/guardian and patient assent * Wash out of 4 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas, 2 weeks in case of vincristine alone; 6 weeks in case of prior radiotherapy (except palliative radiotherapy on non measurable lesions). * Patients must have recovered from the acute toxic effects of all prior therapy before enrolment into the study * Able to comply with scheduled follow-up and with management of toxicity * All patients with reproductive potential must practice an effective method of birth control while on study. * Female patients aged \> 12 years must have a negative pregnancy test within 7 days before study treatment. * Capable of swallowing oral medication

Exclusion criteria

* Pregnant and breast feeding women. * Uncontrolled intercurrent illness or active infection * Inability to swallow oral medication. * Patients on anticonvulsants will be allowed on study

Design outcomes

Primary

Measure	Time frame
Anti-tumour efficacy	3 YEARS

Secondary

Measure	Time frame
Safety AND Pharmacodynamic Study	3 YEARS

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026